busulfan has been researched along with Lymphopenia in 2 studies
Lymphopenia: Reduction in the number of lymphocytes.
Excerpt | Relevance | Reference |
---|---|---|
" Prophylactic T cell depletion via antithymocyte globulin (ATG) during ASCT conditioning is one of the standards of care for GVHD prophylaxis, although the optimal dosing strategy is still unclear." | 5.56 | Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ( Bene, MC; Blin, N; Chevallier, P; Debord, C; Dubruille, V; Duquesne, A; Eveillard, M; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Bris, Y; Le Gouill, S; Mahe, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Wuilleme, S, 2020) |
" Prophylactic T cell depletion via antithymocyte globulin (ATG) during ASCT conditioning is one of the standards of care for GVHD prophylaxis, although the optimal dosing strategy is still unclear." | 1.56 | Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. ( Bene, MC; Blin, N; Chevallier, P; Debord, C; Dubruille, V; Duquesne, A; Eveillard, M; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Bris, Y; Le Gouill, S; Mahe, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Wuilleme, S, 2020) |
"Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3." | 1.43 | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. ( Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Jullien, M | 1 |
Guillaume, T | 1 |
Peterlin, P | 1 |
Garnier, A | 1 |
Le Bourgeois, A | 1 |
Debord, C | 1 |
Mahe, B | 1 |
Dubruille, V | 1 |
Wuilleme, S | 1 |
Blin, N | 1 |
Touzeau, C | 1 |
Gastinne, T | 1 |
Tessoulin, B | 1 |
Le Bris, Y | 1 |
Eveillard, M | 1 |
Duquesne, A | 1 |
Moreau, P | 1 |
Le Gouill, S | 1 |
Bene, MC | 1 |
Chevallier, P | 1 |
Jang, JE | 1 |
Kim, YR | 1 |
Kim, SJ | 1 |
Cho, H | 1 |
Chung, H | 1 |
Lee, JY | 1 |
Park, H | 1 |
Kim, Y | 1 |
Cheong, JW | 1 |
Min, YH | 1 |
Kim, JS | 1 |
2 other studies available for busulfan and Lymphopenia
Article | Year |
---|---|
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Hos | 2020 |
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2016 |